{
    "ticker": "OMRNY",
    "name": "Omeros Corporation",
    "description": "Omeros Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapeutics for a range of medical conditions. Founded in 1994 and headquartered in Seattle, Washington, Omeros is dedicated to addressing unmet medical needs through its proprietary platform technologies. The company is best known for its lead product, Omidria, a drug used during cataract surgery to prevent intraoperative miosis and to maintain pupil dilation. This product has been pivotal in improving surgical outcomes and patient satisfaction. Omeros is also advancing a robust pipeline of novel therapeutics targeting various indications, including neurological disorders, pain management, and inflammation. The company's research focuses on the role of the complement system, a part of the immune system that has been linked to numerous diseases, providing a unique approach to drug development. With a commitment to innovation and patient care, Omeros aims to bring transformative therapies to market and improve the quality of life for patients worldwide.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "Seattle, Washington, USA",
    "founded": "1994",
    "website": "https://www.omeros.com",
    "ceo": "Gregory A. Demopulos",
    "social_media": {
        "twitter": "https://twitter.com/OmerosCorp",
        "linkedin": "https://www.linkedin.com/company/omeros-corporation/"
    },
    "investor_relations": "https://investors.omeros.com",
    "key_executives": [
        {
            "name": "Gregory A. Demopulos",
            "position": "CEO"
        },
        {
            "name": "Michael P. P. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Omidria"
            ]
        },
        {
            "category": "Pipeline",
            "products": [
                "OMS721",
                "OMS527"
            ]
        }
    ],
    "seo": {
        "meta_title": "Omeros Corporation | Innovative Biopharmaceuticals",
        "meta_description": "Explore Omeros Corporation, a biopharmaceutical company focused on developing innovative therapeutics to address unmet medical needs. Learn about their products and pipeline.",
        "keywords": [
            "Omeros",
            "Biopharmaceuticals",
            "Omidria",
            "Innovative Therapies",
            "Healthcare",
            "Complement System"
        ]
    },
    "faq": [
        {
            "question": "What is Omeros known for?",
            "answer": "Omeros is known for its lead product Omidria, used in cataract surgery, and its pipeline of innovative therapeutics."
        },
        {
            "question": "Who is the CEO of Omeros?",
            "answer": "Gregory A. Demopulos is the CEO of Omeros Corporation."
        },
        {
            "question": "Where is Omeros headquartered?",
            "answer": "Omeros is headquartered in Seattle, Washington, USA."
        },
        {
            "question": "What are Omeros's main products?",
            "answer": "Omeros's main products include Omidria and a pipeline of therapeutics like OMS721 and OMS527."
        },
        {
            "question": "When was Omeros founded?",
            "answer": "Omeros was founded in 1994."
        }
    ],
    "competitors": [
        "VRTX",
        "PTCT",
        "XLRN",
        "EDIT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "CELG"
    ]
}